[2025] Use Valid New CCRP Test Notes & CCRP Valid Exam Guide [Q47-Q71]

December 28, 2025 CCRP, SOCRA 0 Comments

[2025] Use Valid New CCRP Test Notes & CCRP Valid Exam Guide [Q47-Q71]

4.7/5 - (3 votes)

[2025] Use Valid New CCRP Test Notes & CCRP Valid Exam Guide

CCRP Actual Questions Answers PDF 100% Cover Real Exam Questions

SOCRA CCRP Exam Syllabus Topics:

Topic	Details
Topic 1	Research Study Closure: This section of the exam measures the skills of Clinical Research Coordinators and covers the activities required to properly conclude a clinical trial. It involves participating in the study closeout visit to verify documentation and account for the investigational product. The domain also includes developing and submitting final closure reports to the IRB, study sponsor, regulatory authorities, and clinicaltrials.gov. Finally, it covers the procedures for archiving study records.
Topic 2	Research Study Start-Up: This section of the exam measures the skills of Clinical Research Coordinators and covers the initial planning and setup of a clinical trial. It involves coordinating the development of the study protocol, ensuring it considers ethical guidelines and regulatory pathways like IND or IDE. It also includes creating essential study documents like informed consent forms and case report forms. The domain covers obtaining necessary approvals from stakeholders like the IRB and sponsor, selecting study sites, training staff, and ensuring the study’s compliance with various laws. Additionally, it involves obtaining the research product and preparing all necessary tools and documentation for the study’s commencement.\|Research Study Implementation: This section of the exam measures the skills of Clinical Research Associates and covers the active management and execution of the clinical trial. It focuses on following the study protocol and standard operating procedures, managing the investigational product, and ensuring ongoing regulatory compliance. The domain includes identifying, documenting, and reporting any study anomalies such as adverse events or protocol deviations. It also involves managing subject recruitment, consent, and retention, as well as maintaining all study records and essential documents. Furthermore, it covers communicating with all study stakeholders and participating in study audits to ensure quality and adherence to regulations.

Topic

Details

Topic 1

Research Study Closure: This section of the exam measures the skills of Clinical Research Coordinators and covers the activities required to properly conclude a clinical trial. It involves participating in the study closeout visit to verify documentation and account for the investigational product. The domain also includes developing and submitting final closure reports to the IRB, study sponsor, regulatory authorities, and clinicaltrials.gov. Finally, it covers the procedures for archiving study records.

Topic 2

Research Study Start-Up: This section of the exam measures the skills of Clinical Research Coordinators and covers the initial planning and setup of a clinical trial. It involves coordinating the development of the study protocol, ensuring it considers ethical guidelines and regulatory pathways like IND or IDE. It also includes creating essential study documents like informed consent forms and case report forms. The domain covers obtaining necessary approvals from stakeholders like the IRB and sponsor, selecting study sites, training staff, and ensuring the study’s compliance with various laws. Additionally, it involves obtaining the research product and preparing all necessary tools and documentation for the study’s commencement.|Research Study Implementation: This section of the exam measures the skills of Clinical Research Associates and covers the active management and execution of the clinical trial. It focuses on following the study protocol and standard operating procedures, managing the investigational product, and ensuring ongoing regulatory compliance. The domain includes identifying, documenting, and reporting any study anomalies such as adverse events or protocol deviations. It also involves managing subject recruitment, consent, and retention, as well as maintaining all study records and essential documents. Furthermore, it covers communicating with all study stakeholders and participating in study audits to ensure quality and adherence to regulations.

NEW QUESTION 47
A research protocol requires patients to complete a patient reported outcome questionnaire in the sponsor’s electronic data capture (EDC) system. What is the source data?

The EDC record

The electronic medical record

A printout of the electronic medical record

A printout of the EDC record

NEW QUESTION 48
A sponsor-investigator implemented a protocol deviation in a device trial to eliminate an immediate hazard.
Before applying this change to all subjects, what must occur?

Obtain IRB/IEC approval

Inform all subjects

Train sub-investigators

Document change in study file

NEW QUESTION 49
In accordance with the ICH E2A Guideline, the sponsor must report an adverse event that is life-threatening, unexpected, and associated with the investigational drug to the regulatory authority as soon as possible but no later than how many calendar days after first knowledge of the event?

1 day

7 days

10 days

15 days

NEW QUESTION 50
Which of the following is one of the responsibilities of an investigator who is NOT a sponsor?

Reporting serious adverse events to the applicable regulatory agency

Ensuring proper monitoring of an investigation at all investigational sites

Ensuring that all participating investigators are promptly informed of significant new adverse events

Maintaining control of the investigational product

NEW QUESTION 51
A study team is preparing to initiate a Phase II trial for a novel colon cancer therapy. By signing the Form FDA 1572, the investigator is certifying that the investigator has:

Read and understood the investigator’s brochure

Completed other relevant research projects

Confirmed that the site’s SOPs are in place

Obtained malpractice insurance

NEW QUESTION 52
A revised protocol added genomic testing to banked tissue samples. Before shipping samples, what must the site do?

Execute material transfer agreement

Ship under dangerous goods requirements

Obtain IRB/IEC approval for revised protocol and ICF

Notify enrolled subjects

NEW QUESTION 53
During an IND study closeout, a monitor discovered remaining investigational product. Which procedures must be followed for disposition?

Sponsor’s procedures

IRB/IEC’s procedures

Regulatory authority’s procedures

Dispensing pharmacy’s procedures

NEW QUESTION 54
Which of the following is an adequate definition of quality assurance for the conduct of a clinical trial?

The systematic plan to review, approve, and monitor biomedical and behavioral research involving human subjects

The planned and systematic actions established to ensure that the trial is performed and the data are generated, documented, and reported in compliance with GCP and the applicable regulatory requirements

An official review by a regulatory authority of documents, facilities, records, and any other resources that are deemed to be related to the trial

The act of reviewing and approving the investigational protocol and informed consent document

NEW QUESTION 55
Which of the following adverse events occurring during a study of an investigational new drug would require the sponsor to notify the FDA as soon as possible but in no case later than seven calendar days after the initial receipt of the information?

Aplastic anemia requiring hospitalization, mentioned in the investigator’s brochure

An infection not related to the investigational drug requiring hospitalization for antibiotic therapy

Death as a result of arrhythmias (irregular heart rhythm), not mentioned in the investigator’s brochure and thought to be related to the use of the drug

Death due to disease progression, mentioned in the investigator’s brochure

NEW QUESTION 56
A research site was invited to participate in an investigational drug study. Which of the following parties is responsible for determining the risk-benefit ratio at the site?

The clinical investigator

The IRB/IEC

The site’s legal counsel

The sponsor

NEW QUESTION 57
Which document was created as a response to unethical WWII human experiments?

Declaration of Helsinki

Nuremberg Code

Belmont Report

Food, Drug, and Cosmetic Act

NEW QUESTION 58
After the sponsor’s auditor completes the final audit report for a Phase II trial with an investigational new drug, which of the following is responsible for providing the audit certificate to the clinical site?

The IRB/IEC

The regulatory authority

The Data Safety Monitoring Board

The sponsor

NEW QUESTION 59
A subject was instructed to do a glucose check 4 times a day for 10 days using an investigational glucose meter. The meter requires one new glucose test strip for each test. The subject received the meter along with
45 glucose test strips. How many unused test strips should the subject have after the 10 days?

NEW QUESTION 60
A subject has creatinine 1.6 mg/dL, slightly above eligibility (#1.5). Investigator believes this is normal for size. When can subject be enrolled?

After sponsor revises eligibility and IRB approves amendment

After repeat test confirms 1.6

After monitor approves deviation

After investigator documents explanation in chart

NEW QUESTION 61
In accordance with the CFR, the IRB/IEC membership must have:

At least seven individuals

A majority of individuals whose primary area of expertise is nonscientific

At least one cleric

At least one individual who is not affiliated with the institution

NEW QUESTION 62
An investigator’s responsibilities for conducting clinical trials include:

Maintaining IRB meeting minutes

Observing preclinical drug effects

Maintaining financial documentation for study staff

Administering or overseeing investigational drug administration

NEW QUESTION 63
Which of the following should a clinical investigator include in a submission to an IRB/IEC for a Phase IV drug study?

The itemized study budget

The amount of payments and compensation to subjects

The drug development and marketing plan

The investigator’s clinical trial agreement with the sponsor

NEW QUESTION 64
A clinical investigator is planning to conduct a quality of life medical device study in the United States. The study has been designed to comply with the approved indication for use of the device. In this situation, who must approve the investigator’s proposed patient recruitment materials?

A scientific review board

The FDA

The Office for Human Research Protections (OHRP)

An IRB/IEC

NEW QUESTION 65
A Phase I clinical trial is initiating. Who is responsible for ensuring that site staff are adequately informed about trial duties?

Sponsor

Program manager

IRB/IEC

Clinical investigator

NEW QUESTION 66
In accordance with the ICH GCP Guideline, who is responsible for the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the case report forms and in all required reports?

The clinical investigator

The quality control specialist

The IRB/IEC coordinator

The contract research organization monitor

NEW QUESTION 67
A subject currently on a clinical trial was hospitalized for 2 days due to a SAE. The subject reported the hospitalization to the investigator at the next study visit. According to the ICH GCP Guideline, when should the investigator report the SAE to the sponsor?

Immediately

Within 7 working days

Within 10 working days

Within 15 working days

NEW QUESTION 68
Which of the following elements should NOT influence the investigator’s ability to obtain endpoint data?

Participant compliance

Complexity of study

Length of study follow-up

Complexity of CRFs

NEW QUESTION 69
Which of the following statements about the investigator’s brochure is correct?

It consists of the instructions for the investigator to conduct the study

It contains a summary of the pharmacological and toxicological effects of the drug in animals, and to the extent known, in humans

It includes financial disclosure information from investigators

It provides documents that permit the evaluation of the conduct of the study and the quality of the data

NEW QUESTION 70
Which document was created by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research and summarizes the basic ethical principles and guidelines for the conduct of research involving human subjects?

The Nuremberg Code

The Declaration of Helsinki

The ICH Guidelines

The Belmont Report

NEW QUESTION 71
The study coordinator for a new Phase III vaccine study is preparing documents for IRB/IEC submission.
According to the ICH GCP Guidelines, which of the following documents should be included in the submission?

Local lab normal ranges

Case report forms

Recruitment materials

The investigators’ CVs